Juvaris BioTherapeutics Inc.
This article was originally published in Start Up
Executive Summary
Juvaris BioTherapeutics Inc.'s technology is an offshoot of gene therapy work originally conducted at Valentis. Researchers there discovered that their DNA/lipid delivery combination elicited a mild immune response at the lowest dose. Juvaris has used the technology to develop two classes of products: JuvImmune is made up of the DNA/lipid combination without an antigen and is intended to boost the immune response. Combined with vaccines, where it boosts the intensity of the immune response, the technology is called JuvaVax.